Stanbio Laboratory is committed to manufacture and market a complete line of high quality clinical diagnostic products with an unmatched level of service and support.
In June 17, 2011, Stanbio Laboratory became part of the EKF Diagnostics Group– a family of international companies focused on the rapidly developing near-patient care and diabetes management markets. With this historic change, the worldwide presence of Stanbio has taken a huge leap forward. Expanded human and financial resources, new distribution partners, innovative products and technologies are now supported by an even deeper management team of extraordinarily experienced and talented individuals. Our parent company, EKF Diagnostics Holdings plc, is publically traded on the London Stock Exchange and is providing the foundation for our tremendous growth opportunities globally.